US 8063066
MAPK/ERK kinase inhibitors
granted A61PA61P1/04A61P1/18
Quick answer
US patent 8063066 (MAPK/ERK kinase inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61P, A61P1/04, A61P1/18, A61P11/06, A61P13/08